High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: multicentre randomized controlled clinical trial

JAVIER MARIANI; LAURA ANTONIETTI; CARLOS DANIEL TAJER; LEÓN FERDER; FELIPE INSERRA; MAXIMILIANO CARMONA; WALTER MANUCHA

PLOS ONE

PUBLIC LIBRARY SCIENCE

Lugar: San Francisco; Año: 2022 vol. 17 p. 1 - 16

1932-6203

Background: The role of oral vitamin D 3 supplementation for hospitalized patients with COVID-19 remains to be determined. The study was aimed to evaluate whether vitamin D 3 supplementation could prevent respiratory worsening among hospitalized patients with COVID-19.Methods and Findings: We designed a multicentre, randomized, double-blind, sequential, placebo-controlled clinical trial. The study was conducted in 17 second and third level hospitals, located in four provinces of Argentina, from 14 August 2020 to 22 June 2021. We enrolled 218 adult patients, hospitalized in general wards with SARS-CoV-2 confirmed infection, mild-to-moderate COVID-19 and risk factors for disease progression. Participants were randomized to a single oral dose of 500 000 IU of vitamin D 3 or matching placebo. Randomization ratio was 1:1, with permuted blocksand stratified for study site, diabetes and age (≤60 vs >60 years). The primary outcome was the change in the respiratory Sepsis related Organ Failure Assessment score between baseline and the highest value recorded up to day 7. Secondary outcomes included the length of hospital stay; intensive care unit admission; and in-hospital mortality. Overall, 115 participants were assigned to vitamin D 3 and 105 to placebo (mean [SD] age, 59.1 [10.7] years; 103 [47.2%] women). There were no significant differences in the primary outcome between groups (median [IQR] 0.0 [0.0 - 1.0] vs 0.0 [0.0 - 1.0], for vitamin D 3 and placebo, respectively; p = 0.925). Median [IQR] length of hospital stay was not significantly different between vitamin D 3 group (6.0 [4.0 - 9.0] days) and placebo group (6.0 [4.0 - 10.0] days; p = 0.632). There were no significant differences for intensive care unit admissions (7.8% vs 10.7%; RR 0.73; 95% CI 0.32 to 1.70; p = 0.622), or in-hospital mortality (4.3% vs 1.9%; RR 2.24; 95% CI 0.44 to 11.29; p = 0.451). There were no significant differences in serious adverse events (vitamin D 3 = 14.8%, placebo=11.7%). Conclusions: Among hospitalized patients with mild-to-moderate COVID-19 and risk factors, a single high oral dose of vitamin D 3 as compared with placebo, did not prevent the respiratory worsening. Trial Registration: ClincicalTrials.gov Identifier: NCT04411446